![]() ![]() You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. The firm's 50 day moving average price is 136.61 and its 200 day moving average price is 145.41. The firm has a market cap of 8.04 billion, a PE ratio of -49.45, a PEG ratio of 0.72 and a beta of 0.74. The company has a debt-to-equity ratio of 1.71, a quick ratio of 2.32 and a current ratio of 3.06. Between 66-89% of retail investor accounts lose money when trading CFDs. Shares of JAZZ opened at 125.61 on Tuesday. Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. This keeps our service impartial and ad-free. Please open a trading account through our links to tip us. ![]() And Wall Street continues to be enamored with the drugmaker, which has a consensus buy rating, according to Yahoo Finance. It does not constitute financial advice.Īffiliate links: This blog is supported by its readers. Over the past year, the company's shares are up by 17. ![]() Information published on this website is factual and for information purposes only. is an online publication that covers Forex and CFD providers. We do not accept deposits, do not process payments, do not advise on investments, do not deal in investments (as agent or principal) and do not arrange deals in investments. Information published on this website is not directed at residents of the United Arab Emirates or Belgium and is not intended for use by any person in any jurisdiction where such use would be contrary to local law or regulation.ĭisclaimer: is not a Forex or a CFD provider. To read this article on click is a trademark of Media Vest FZ-LLC, a company incorporated with the Dubai Development Authority in the United Arab Emirates under registration number 101647. Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. With strong valuation and earnings metrics, a good Zacks Rank, and top-tier Value and VGM Style Scores, investors should strongly think about adding JAZZ to their portfolios. JAZZ has an average earnings surprise of 10.9%. The Zacks Consensus Estimate has increased $0.00 to $17.35 per share. One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2022. Value investors don't just pay attention to a company's valuation ratios positive earnings play a crucial role, too. Value investors should also note JAZZ's Price/Sales ratio of 2.4X. Additionally, JAZZ has a PEG Ratio of 0.7 and a Price/Cash Flow ratio of 5.9X. Shares are currently trading at a forward P/E of 7.8X for the current fiscal year compared to the Medical - Drugs industry's P/E of 14.5X. JAZZ is a Zacks Rank #1 (Strong Buy) stock, with a Value Style Score of B and VGM Score of B. Xywav was also approved for treating idiopathic hypersomnia (IH). Both drugs are approved for treating cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients. Xywav is a low-sodium formulation of Jazz’s legacy drug, Xyrem, which was launched in 2020. Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and. The company derives the majority of its revenues from its sleep disorder drugs - Xywav and Xyrem. At Yahoo Finance, you get free stock quotes, up-to-date news. Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks.ĭublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience and oncology. Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |